Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777666 | 1.00 | RAB9A (0.47) | RAB9ASMN1; SMN2DAGLAABHD6PRCP | |
| SCHEMBL1776470 | 0.97 | RAB9A (0.46) | RAB9ASMN1; SMN2PRCPHDAC1PDE10A | |
| SCHEMBL1777093 | 0.90 | OPRM1 (0.46) | DAGLAABHD6PRCPHDAC1 | |
| SCHEMBL1778710 | 0.83 | HCRTR1 (0.41) | RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1778712 | 0.83 | HCRTR1 (0.41) | RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1777216 | 0.82 | DAGLA (0.41) | SMN1; SMN2DAGLAABHD6DAGLBALDH1A1 | |
| SCHEMBL1777217 | 0.82 | DAGLA (0.41) | SMN1; SMN2DAGLAABHD6DAGLBALDH1A1 | |
| SCHEMBL1776732 | 0.82 | HCRTR1 (0.43) | RAB9ASMN1; SMN2PRCP | |
| SCHEMBL1777694 | 0.81 | CNR1 (0.45) | SMN1; SMN2PRCPHDAC1ALDH1A1 | |
| SCHEMBL1778706 | 0.81 | HCRTR1 (0.42) | RAB9ASMN1; SMN2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | RAB9A 1985/4885SMN1; SMN2 3363/4885DAGLA 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.